

T02T27 " 263T00T

1/10

		4-11-96	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	5-10-96	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml
11	PU	MR1 ug/ml				PU	MR1 ug/ml		
AR	2.5	ND	ND	4.6 (0.26)	0	3	ND	ND	1.7 (0.12)
AL	4	ND	ND	1.2 (0.05)	0	4	ND	ND	6.5 (2.3)
AN	4	ND	ND	2.8 (0.08)	1.24 (0.06)	"	"	"	"
BR	4	ND	ND	0	0	"	"	"	"
BN	3	ND	ND	8.8 (0.04)	0.47 (0.05)	4+	ND	ND	> 25.5 (1.6)
CL	2	0	6.5 (0.3)	5.9 (0.36)	6.5 (0.84)	2	0	21.1 (2.2)	> 67.5 (1.97)
CLR	2	15.9 (2.1)	0	0	0	3	0.9 (0.1)	0	1.5 (0.7)
DR	1.5	25.7 (2.5)	0	18.1 (0.7)	9.5 (0.9)	2	4.9 (1)	0	ND
DN	1	36.1 (1.6)	0	0	0	2	1.8 (0.2)	0	1.5 (0.3)
CN	2	0	0.8 (0.04)	0	0	"	"	"	ND
CR	3	0	1.4 (0.13)	0	0	"	"	"	ND

		10-2-96	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml	11-15-96	MR1 ug/ml	ANTI-MR1 ug/ml
	PU	MR1 ug/ml					PU		
4	ND	ND	ND	6.2 (0.8)	3.2 (0.2)	0.4 (.06)	"	"	"
"	"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"	"
4	0	28.5 (3.9)	21.1 (2.7)	13.5 (1.5)	1 (.02)	4	0	10 (0.8)	"
3	0	20.6 (1.9)	11.2 (3.6)	1.6 (0.2)	1.7 (0.1)	"	"	"	"
4	0	0.49 (0.03)	12.1 (0.9)	5.6 (0.1)	0.2 (.01)	4	0	0	0
2	59 (4.1)	0	3.2 (0.5)	0.0	1.2 (.06)	tr	34 (2.1)	0	0
"	"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"	"

FIG. 1

LABEL #	A	B	C	D	E	F	G	H	I	J	K	L	M
	2-21	2-21-96	3-15	3-20	4-3	4-10	4-17	4-23	5-8	5-16	6-10	7-10	8-14
STUDY II:A Hlg R		1.5	2	3	2.5	2.5	3				4+	4	4
	L	1.6	2	3	4	4					4+	DEAD/G+19	
	N	2.5	4	4	4	4					DEAD 6/4		
STUDY II:B Hlg R	1		0.5	2	4	4					DEAD 6/10	DISAPPEAR	
	N	1	1	3	2.5	3					4+	DISAPPEAR	
STUDY II:C MR1 R	1	2	3	3	3	3		DEAD 4/29					
	L	1.5	1 TRACE	2	2	2	2		NC	NC	2	4	4
	N	1	2	2	2	NC	DEAD						
	LR	1	1	2	NC	2	2		2	3			
STUDY II:D MR1 R	1	0.5	1	NC	1.6	11/2	1.5	2	NC	2	NC	3	3
	N	1	1	1	1	1	NC				2	2	2
								2	2	2		2	2

[illegible]

FIG. 2

TOTAL = 2237007

		PRE-5-2-96			10-4-96	9/18 5 INJ					11-15-96	10/15 6INJ
V	PU	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml	
AR	tr	13.4(1.3)	4.3(0.5)	"	"	"	"	"	"	"	"	"
AL	tr	0	0	"	"	"	"	"	"	"	"	"
AN	tr	5.4(0.6)	1.3(0.3)	"	"	"	"	"	"	"	"	"
BR	2	2.9(0.1)	0	"	"	"	"	"	"	"	"	"
BL	2	0.8(0.03)	0	"	"	"	"	"	"	"	"	"
BN	2	0	0	4+	ND	ND	13.2 (1.1)	3.3 (0.3)	4+	ND	ND	
BLR	2	0	0	"	"	"	"	"	"	"	"	"
CR	2	1.2(0.1)	2.3(0.3)	4	30 (4.6)	ND	0	0	"	"	"	"
CL	1	0.9(0.1)	0	1	0	926(51)	2.6 (0.3)	0	1	0	0.2(0.00)	
CN	1	0	0	1	68 (3.5)	ND	0	0	1	39 (6.4)	0	
OR	1	0	0	2	143 (27)	ND	0	0	1	77.5(8.4)	0	
DL	2	2.9(0.2)	0	1.5	36.6 (6.7)	ND	0	0	1.5	30.4 (6.8)	0.5 (0.00)	
DN	tr	1.9(0.1)	0		"	"	"	"	"	"	"	"
DLR	1	0	0		"	"	"	"	"	"	"	"

FIG. 3

T0247 263700

	6-8-96	6-17	4-10	4-10	4-26	7-3	7-10	7-17	7-25	7-31	8-14	8-21	8-28	9-4
STUDY V:A Hlg R	TRACE	2	DEAD 6-21											
L NC	TRACE	3		4	4	4	4	4		4			DEAD 8-24	
N TRACE	TRACE	3		4	4	4	4	NC		4				
STUDY V:B Hlg R	2	4		NC	2									
L NC	2	3		NC	4	4	4	NC	4+		DEAD 8-13			
N 2/SICK	NC	2	2	NC	2	2	2	2	2	2	3	3		3
LR TRACE	DEAD 5-12													
STUDY V:C MR1 R	2	2	2	NC		3	3	3	4					
L 1	1	2	2	1	1	1	1	1	1	1	4	4		4
N 1	1	1	1	1	1	1	1	1	NC	1	1	1		1
STUDY V:D MR1 R	NC	1	1	NC	1	2	2	2	2	2	2	2		2
L 2	2	2	2	NC	2	2	2	1.5	1.5	1.5	NC 1.5	NC 1.5		1.5
N TRACE	TRACE	NC	1	NC	1	1	1	1	1	NC 1		2	2	2
LR NC	1	2	2	NC	NC	NC	3	NC	2	3	DEAD 8-14			

9-11	9-25	10-9	10-23	10-30	11-6	11-13	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
4	DEAD 9-23												
4+	4+	4+	4+	4+	4+	4+	4+	4+	4+	4+	4+	4+SICK	DEAD 12-31
4		DEAD 10-9											
1	1	1	NC	1	1	1	1	1	1	1	1	TRACE	TRACE
1	1	1	1	1	1	1	1	1	NC	1	1	NC	TRACE
2	NC	2	2	1	1	1	1	1	1	1	1	1	1
NC 1:5	1:5	1:5	NC	1:5	1:5	1:5	1:5	1:5	TRACE	NC	TRACE	TRACE	TRACE
NC 2	DEAD 9-30												

FIG. 4

VII PU	9-30-96 MR1 ug/ml	9/3-7 INJ ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml	PU	11-1-96 MR1 ug/ml	10/1-6 inj. ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml
AN 4	ND	ND	2.4(0.3)	0	0.14(0.03)	"	"	"	"	"	"
BR 4	ND	ND	8.8(0.7)	8.3(0.1)	1.6(0.1)	4	ND	ND			1.2 (0.1)
BL 4	ND	ND	8.3(0.1)	10.1(1.1)	0.6(0.1)	4	ND	ND			0.7 (0.06)
CR 1	35.7 (1.5)	ND	2.7(0.6)	0	0.6(0.1)	1	22.5 (5)	0	1.5 (0)	1.7 (0.2)	1.4 (0.4)
CL 1.5	32(3)	ND	2.0(0.2)	0	0.6(0.1)	1.5	24 (5)	0	0	0.4 (0.07)	0.7 (0.06)
CN 3	24(0.6)	0	2.0(0.1)	1.5(0.1)	0.6(0.06)	3	0	5.3 (0.6)	3.5 (0)	3.7 (0.2)	1.4 (0.4)
CLR 2	36.1(2.8)	0	0	0	0.8(0.06)	1	6.4 (0.6)	0.05(0.002)	1.8 (0)	1 (0.1)	1.4 (0.4)
DR 1	27.6(3.9)	0	2.7(0.6)	0	1.0(0.01)	1	5.9 (0.9)	0.05(0.003)	2.5 (0.9)	2.9 (0.2)	1.3 (0.3)
DL 2	51.3(5.4)	ND	0	0	0.6(0.1)	2	23.6(4)	0	0	0	0.6 (0.1)
DN 1.5	20(4)	0	3.6(1.38)	0	1.1(0.1)	1.5	4.8(0.9)	0	0	0	

11-20-96		10/1-6 inj.	
PU	MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml
"	"	"	"
"	"	"	"
4	ND	ND	0
1	38.5 (5.7)	0	0
tr	47.3 (2.5)	0	98.2 (1.8)
(3)	313.6 (52)	0	49.5 (0.2)
1	16.2 (0.9)	0	0
1	40.6 (7.3)	0 Rev BUN 11/1	0
1	71 (6.6)	0	0
1.5	85.5 (7.7)	0	0

FIG. 5

	6-24	7-10	7-17	7-25	7-31	8-14	8-21	8-28	9-4	9-11	9-25	10-2	10-9
STUDY VII:A Hlg R	4 SICK?	4+	4			4				DEAD9-5			
RR	1	4	4			4				DEAD9-9			
N	4	4	4			4				4		DEAD9-30	
LR	4	4	4			4				4	DEAD9-23		
STUDY VII:B Hlg R	0.5	4	4			4				4	4	4	
L	2	4	4				NC	4		NC	4	4	
N	3.5	4	4			DEAD8-11							
STUDY VII:C MR1 R	NC	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1	NC
L	TRACE	1.5	NC	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5	1.5
N	1.5	2	2	NC	NC	2	2	2	2	3	NC	3	3
LR	NC	2	2	2	2	2	2	2	2	NC	2	2	2
STUDY VII:D MR1 R	2	2	2	2	2	2	2	2	2	2	2	1	1
L	1.5	1.5	1.5	1.5	1.5	1.5	2	2	2	1.5	2	2	2
N	1.5	1.5	1.5	1.5	1.5	1.5	NC	1.5	1.5	1.5	NC	NC	1.5

[illegible]

FIG. 6

		PRE 10-14-96			11/25/96		
X	PU	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml
AR	1	4.2(1.2)	0	2	64.8 (3.3)	24.8 (1)	1.7 (0.08)
AL	1	2.5(0.3)	0.2(0.0)	2	107.6 (4.2)	11.3 (1)	1.8 (0.1)
AN	1	5.1(0.7)	4.2(0.5)	4	0	0	0.2 (0.01)
ALR	tr	0.3(0.1)	0	1	40.9 (1.5)	23 (1.5)	1.8 (0.04)
BR	2	49.0(3.5)	3.3(0.1)	3	10.8 (1.6)	3.9 (0.4)	5.1 (0.1)
BL	1	3.8(1.0)	0	3	4.7 (0.2)	3.1 (0.1)	2.1 (0.03)
BN	tr	5.1(0.02)	0	1	26.8 (3.8)	15.9 (2.6)	7.4 (0.8)
BLR	1	3.0(0.3)	0	1	22.1 (3.2)	23.1 (0.4)	5.9 (0.6)
CR	1	17.8(2.8)	6.7(0.8)	1	124 (0)	0	2.7 (0.04)
CL	1	0	18.9(2.2)	1	140 (23)	68.7 (5.6)	2.8 (0.1)
CN	1	1.03(0.3)	0.6(0.10)	1	0	0	1.3 (0.1)
CLR	tr	22.6(2.08)	7.7(1.06)	0.5	18.6 (1.6)	6.1 (0.3)	1.5 (0.1)
DR	3	0	0	4	70.3 (7.5)	0	0.9 (0.03)
DL	1	4.3(0.6)	3.6(0.6)	1	8.4 (0.1)	0	2.2 (0.2)
DN	tr	5.1(1.1)	8.6(0.1)	0.5	42.5 (4.6)	0	
DLR	tr	0	0	0.5	0	0	

FIG. 7

T0227 228500T

	9-16	9-25	10-2	10-9	10-14	10-23	10-30	11-6	11-13	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
STUDY X:A Ha4/8 R					1	2	2	2	2	2	NC	2	3	3	3	4
L					1	1	1	1	1	1	2	NC	2	3	3	4
N					1	2.5	2.5	3	4+	4+	4+	4+	2	DEAD12-18	3	3
LR					TRACE	TRACE	1	1	1	1	1	4	4+	4		
STUDY X:A Ha4/8 R					2	2	NC	3	NC	3	NC	3	NC	3	3	4
L					1	1	1	2	NC	2	3	3	3	4	4	4
N					TRACE	1	1	1	1	1	1	2	1	3	4	4
LR					1	1	1	1	1	1	1	1	1	1	1	NC
STUDY X:C MR1 R					1	1	1	1	1	1	1	1	1	1	1	1
L					1	1	1	1	1	1	1	1	1	1	1	1
N					1	1	1	1	NC	1	1	NC	1	1	2	2
LR					1	1	1	1	1	1	1	1	1	1	1	1
STUDY X:D MR1 R					TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	1
L					3	3	3	4	4	4	4	4	4	4	1	4
N					1	1	NC	1	1	1	1	NC	1	1	1	3
LR					TRACE	TRACE	TRACE	TRACE	NC	TRACE	TRACE	TRACE	TRACE	TRACE	1	NC
					TRACE	TRACE	TRACE	TRACE	NC	TRACE	TRACE	TRACE	TRACE	TRACE	NC	NC

FIG. 8

VI	PU	10-2-96		10/1 -8 INJ		11-1-96		10/1 -8 INJ		ANTI-DSDNA		ANTI-DSDNA ug/ml
		MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-DSDNA ug/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-DSDNA ug/ml	ANTI-MR1 ug/ml	ANTI-DSDNA ug/ml	ANTI-MR1 ug/ml	
DN	4	8.1 (1.4)	0.64 (0.8)	12.9(0.4)	"	0	1	27 (6)	0	3.2 (1.3)	1.3 (0.08)	"
ER	1	153 (7.8)	ND	7.4(0.3)	"	0	3	0	4.9(0.2)	0	1.7 (0.2)	"
EL	3	46.7 (4.6)	0.35 (0.09)	3.1(0.6)	"	0	"	"	"	"	"	"
EN	3	25 (3.5)	0	5.6(0.6)	"	0	"	"	"	"	"	"

11-20-96		11/5 -9 INJ	
PU	MR1 ug/ml	ANTI-MR1 ug/ml	
"	"	"	"
1	90 (9.8)	"	0
3	151.7 (4.6)	0.5 (.04) REV BUN 11/1	"
"	"	"	"

FIG. 9

	6-24	7-10	7-17	7-25	7-31	8-14	8-21	8-28	9-4	9-11	9-25	10-2
STUDY VI:A Hlg R	3.5	3	3	4		DEAD8-10						
N		3	NC	3	4	4						
STUDY VI:B Hlg N	4	4	4			4				4	DEAD9-15	
STUDY VI:C Hlg N	1.5	3	3	4+		4				4+	4+	DEAD9-30
STUDY VI:D MR1 N	4	4	4			4				DEAD9-11		
STUDY VI:E MR1 R	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	4	4	4
L	2.5	2.5	2.5	2.5	NC	3	3	3	3	TRACE	NC	1
N	2.5	2.5	NC	2.5	3	3	2.5	3	3	3	3	NC
												3

10/10

10-9	10-23	10-30	11-6	11-15	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
DEAD10-20											
NC	1	1	1	1	1	1	1	1	1	1	1
3	3	3	3	3	3	3	NC	3	DEAD12-18		
3 DEAD10-21											

FIG. 10